Skip to main content
SpringerLink
Log in

Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer

  • Original Article
  • Published:
Chinese Journal of Cancer Research

Abstract

Objective

To investigate the relationship between postoperative metastasis and circulating levels of osteopontin in non-small cell lung cancer (NSCLC).

Methods

The expression of osteopontin mRNA were detected with RT-PCR technique. The circulating levels of osteopontin were measured through ELASA in 46 NSCLC cases that had not been received any anti-cancer treatment at the time of sampling. The tissues from fifteen patients with benign pulmonary diseases were studied as control group.

Results

The overall median mRNA expression level of osteopontin was approximately 70-fold higher in tumor tissues than in matched normal lung tissues (P<0.001). Over-expression of osteopontin mRNA was significantly associated with clinical stage (P=0.009). Advanced disease states had higher circulating level of osteopontin (stage I+II versus stage III+VI). In multivariate analysis, stage was the only independent factor influencing circulating levels of osteopontin. All patients were followed up for 12 months, 2 of the 46 patients with both osteopontin mRNA expression and elevated plasma osteopontin levels had local recurrence and 10 had distant metastasis. There was a significant difference in the osteopontin levels between metastasis group and non-metastasis group.

Conclusion

Preoperative plasma levels of osteopontin are significantly associated with post-operative metastasis in advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Donati V, Boldrini L, Dell’Omodarme M, et al. Osteopontin expression and prognostic significance in non-small cell lung cancer. Clin Cancer Res 2005; 11:6459–6465.

    Article  PubMed  CAS  Google Scholar 

  2. Chan DC, Earle KA, Zhao TL, et al. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res 2002; 8:904–912.

    PubMed  CAS  Google Scholar 

  3. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003; 22:6524–6536.

    Article  PubMed  CAS  Google Scholar 

  4. Tuck AB, Arsenault DM, O’Malley FP, et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999; 18:4237–4246.

    Article  PubMed  CAS  Google Scholar 

  5. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12:1507–1514.

    Article  PubMed  CAS  Google Scholar 

  6. Hirama M, Takahashi F, Takahashi K, et al. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003, 198:107–117.

    Article  PubMed  CAS  Google Scholar 

  7. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997; 111:1710–1717.

    Article  PubMed  CAS  Google Scholar 

  8. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11:279–303.

    Article  PubMed  CAS  Google Scholar 

  9. Reinholt FP, Hultenby K, Oldberg A, et al. Osteopontin — a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990; 87: 4473–4475.

    Article  PubMed  CAS  Google Scholar 

  10. Giachelli CM, Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000;19:615–622.

    Article  PubMed  CAS  Google Scholar 

  11. Shijubo N, Uede T, Kon S, et al. Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncod 2000; 11:135–146.

    CAS  Google Scholar 

  12. Denhardt DT, Noda M, O’Regan AW, et al. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival. J Clin Invest 2001; 107:1055–1061.

    Article  PubMed  CAS  Google Scholar 

  13. Geissinger E, Weisser C, Fischer P, et al. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res 2002; 62:4820–4828.

    PubMed  CAS  Google Scholar 

  14. Xie Y, Sakatsume M, Nishi S, et al. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 2001; 60:1645–1657.

    Article  PubMed  CAS  Google Scholar 

  15. Thalmann GN, Sikes RA, Devoll RE, et al. Osteopontin: possible role in prostate cancer progression. Clin Cancer Res 1999; 5:2271–2277.

    PubMed  CAS  Google Scholar 

  16. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94:513–521.

    PubMed  CAS  Google Scholar 

  17. Hu Z, Lin D, Yuan J, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005; 11:4646–4652.

    Article  PubMed  CAS  Google Scholar 

  18. Coppola D, Szabo M, Boulware D, et al. Correlation of Osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004, 10:184–190.

    Article  PubMed  CAS  Google Scholar 

  19. Tuck AB, Hota C, Chambers AF. Osteopontin (OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 2001; 70:197–204.

    Article  PubMed  CAS  Google Scholar 

  20. Schorge JO, Drake RD, Lee H, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 2004; 10:3474–3478.

    Article  PubMed  CAS  Google Scholar 

  21. Wong TS, Kwong DL, Sham J, et al. Elevation of plasma osteopontin level in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2005; 31:555–558.

    Article  PubMed  CAS  Google Scholar 

  22. Rudland PS, Platt-Higgins A, EI-Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62:3417–3427.

    PubMed  CAS  Google Scholar 

  23. Isa S, Kawaguchi T, Teramukai S, et al. Serum osteopontin levels are highly prognostic for survival in advanced non-small cell lung cancer: results from JMTO LC 0004. J Thorac Oncol 2009; 4:1104–1110.

    Article  PubMed  Google Scholar 

  24. Mack PC, Redman MW, Chansky K, et al. Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 2008; 26:4771–4776.

    Article  PubMed  CAS  Google Scholar 

  25. Chang YS, Kim HJ, Chang J, et al. Elevated circulating level of osteopontin is associated with advanced disease state of non-small cell lung cancer. Lung Cancer 2007; 57:373–380.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery and Central Laboratory, Beijing Key Laboratory of Respiratory and Circulation, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, 100020, China

    Yong Liang, Hui Li, Bin Hu, Xing Chen, Jin-bai Miao, Tong Li, Bin You, Qi-rui Chen, Yi-li Fu, Yang Wang & Sheng-cai Hou

Authors
  1. Yong Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hui Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bin Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jin-bai Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bin You
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Qi-rui Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yi-li Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sheng-cai Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hui Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liang, Y., Li, H., Hu, B. et al. Elevated circulating levels of osteopontin are associated with metastasis in advanced non-small cell lung cancer. Chin. J. Cancer Res. 23, 64–68 (2011). https://doi.org/10.1007/s11670-011-0064-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11670-011-0064-9

Key words

Search

Navigation